XBiotech Inc. reported positive results from a phase 3 study evaluating its Hutruo antibody therapy as a potential treatment of advanced colorectal cancer, also known as bowel cancer and colon cancer.

According to the results, 40% of the patients who received the treatment achieved the main goal of reduced disease progression, as measured by the combination of patient-reported symptoms and radiography. This was nearly double compared to patients who received placebo.

Further, patients who achieved the primary endpoint demonstrated substantially improved survival outcomes, with a median survival of 11.7 months compared to the 5.7 months for those who did not.